Monday 9 November 2026 Export KRRO’s income statement to Excel — free account

Korro Bio, Inc.

KRRO

Healthcare Biotechnology

Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024.

Revenue: −86.3%
EPS: +61.0%
Free cash flow: +12.1%

Quarter to June 2026, against a year earlier

Insider buying

14.75 0.02 +0.14%

Follow KRRO

Alert me

Market cap: $202.5M
P/E: n/m
Fwd P/E: n/m
Dividend yield: —
F-score: n/a
ROIC: 0.00%
Net debt / EBITDA: 0.6×
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Net bought: $16.0M
Trades: 15 sells · 12 buys
Ownership: 41.7%

Capital & Financial Ratios $m

Size

Market Cap 202

Revenue ttm 6

Net income ttm (107)

Free cash flow ttm (68)

Net debt Q (115)

Valuation

P/E n/m

Forward P/E n/m

Price / sales 40.7

Forward P/S Powerpack

Price / FCF n/m

Price / book 2.5

Financial health

Current ratio Q 9.6

Debt / equity Q n/m

Interest coverage Q (53.2)

Growth

Revenue growth Q −86.3%

Operating income growth Q +26.1%

EPS, this year +60.8%

EPS, next year A +1.8%

Revenue, next year A −94.1%

EPS, past 5 yrs —

EPS, next 5 yrs A +31.4%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 98.44%

10-year low 10-year high

P/B against its own 10 years 77.56%

10-year low 10-year high

EV/Sales against its own 10 years 93.54%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	166	126	75	115
Receivables	—	2	1	—
Inventory	—	—	—	—
Other	4	—	—	—
	173	132	82	121

	2023	2024	2025	Q'26
Payables	7	4	2	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	19	15	12	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(44.30%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(23.20%)	(7.42%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.14 Actual −0.98

−5.97 −4.56 −3.15 −1.74 −0.33

Q4 FY25 Miss −3.39

Q1 FY26 Miss −0.09

Q2 FY26 Beat +0.47

Q3 FY26 Beat +0.16

Q4 FY26 — Mar 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−1.93	−5.32	Miss by 3.39
Q1 FY26	−1.60	−1.69	Miss by 0.09
Q2 FY26	−1.54	−1.07	Beat by 0.47
Q3 FY26	−1.14	−0.98	Beat by 0.16
Q4 FY26	−1.29	—	Reports 11 March 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.69)	(1.07)	—	—	—
’25	(2.49)	(2.74)	(1.92)	(5.32)	(12.48)
’24	(2.44)	(2.43)	(2.26)	(2.26)	(9.37)
’23	(72.08)	(63.95)	(65.11)	(4.81)	(53.08)
’22	(33.50)	(30.50)	(27.50)	(24.50)	(227.58)
’21	(30.00)	(26.00)	(36.50)	(31.00)	(123.50)
’20	(8.00)	(9.50)	(8.00)	(15.00)	(41.00)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	3	1	1	1	6
’24	—	—	—	—	2
’21	5	9	—	—	14
’20	7	9	11	10	37

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(17)	—	—	—
’25	(24)	(19)	(17)	(18)	(79)
’24	(22)	(15)	(16)	(7)	(60)
’23	(20)	(15)	(12)	(21)	(67)
’22	(17)	(13)	(12)	(11)	(54)
’21	(25)	(18)	(15)	(18)	(76)
’20	(9)	(10)	(11)	(15)	(45)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(17)	—	—	—
’25	(25)	(19)	(17)	(18)	(79)
’24	(28)	(21)	(21)	(9)	(78)
’23	(21)	(19)	(12)	(23)	(75)
’22	(17)	(13)	(12)	(16)	(59)
’21	(26)	(20)	(15)	(18)	(79)
’20	(10)	(11)	(12)	(19)	(52)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	29	37	14	—	—	2	6	6		(22.3%)	0	1	—	(69.7%)
	Gross margin, %	—	0.00	0.00	100.00	100.00	100.00	0.00	—	100.00	100.00	100.00		+100.0 pt	Powerpack Korro Bio, Inc.’s next three years, line by line Analysts expect revenue to shrink 69.7% a year to 2028 — slower than the −22.3% of the last 6 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	(20)	(19)	(19)	(26)	(85)	(58)	(81)	(83)	(117)	(106)		+24.5%
	EBT margin, %	—	0.00	0.00	(64.76)	(71.59)	(601.87)	0.00	0.00	(3,674.15)	(1,824.52)	0.00		(1,824.5) pt
	Net income	—	(20)	(19)	(19)	(27)	(85)	(58)	(81)	(84)	(117)	(107)		+24.6%
Per share, $
Per share, $	Revenue	—	0.00	0.00	167.32	57.33	20.48	0.00	0.00	0.25	0.68	0.00		n/m
	Earnings	—	(1,439.33)	(626.41)	(114.50)	(41.00)	(123.50)	(227.58)	(53.08)	(9.37)	(12.48)	(10.00)		(44.8%)
	Cash flow	—	(1,036.45)	(556.34)	197.78	(70.05)	(110.71)	(210.37)	(44.00)	(6.73)	(8.36)	(3.86)		(45.3%)
	Capex	—	(132.13)	(14.25)	(6.15)	(10.34)	(4.24)	(20.14)	(5.12)	(2.01)	(0.06)	(0.02)		(62.2%)
	Free cash flow	—	(1,168.58)	(570.59)	191.63	(80.39)	(114.95)	(230.51)	(49.13)	(8.74)	(8.42)	(3.87)		(46.0%)
	Book value	—	0.00	1,321.11	967.39	298.39	190.43	254.24	111.13	17.98	5.48	5.86		n/m
	Shares, m	—	0	0	0	1	1	0	2	9	9	12		+125.4%
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	—	—	0.00	0.00	0.00		0.0
	P/S	—	—	—	0.00	30.75	5.00	—	—	9.63	11.77	40.65		11.4
	P/B	—	—	—	0.91	5.91	1.35	—	—	2.12	1.46	2.52		2.3
	EV/Sales	—	—	—	0.00	25.21	1.72	—	—	6.57	2.88	25.53		7.3
	EV/FCF	—	—	—	(1.98)	(17.98)	(0.77)	—	—	(2.97)	(0.23)	(2.39)		(4.8)
Cash, $m
Cash, $m	Operating cash flow	—	(15)	(17)	34	(45)	(76)	(54)	(67)	(60)	(79)	(68)		+23.4%
	Capex	—	(2)	0	(1)	(7)	(3)	(5)	(8)	(18)	(1)	0		(14.8%)
	Free cash flow	—	(16)	(17)	33	(52)	(79)	(59)	(75)	(78)	(79)	(68)		+21.7%
Balance, $m
Balance, $m	Working capital	—	16	39	169	198	123	48	153	117	70	108		+20.6%
	Net debt	—	29	43	(217)	(205)	(116)	(55)	(166)	(126)	(75)	(115)		n/m
	Shareholders’ equity	—	—	40	167	192	131	65	170	160	51	103		+3.5%
Returns, %
Returns, %	ROA	—	(90.85)	(86.06)	(14.79)	(10.87)	(37.63)	(44.80)	(54.96)	(37.32)	(69.03)	(62.03)		+21.8 pt
	ROIC	—	(35.44)	(14.24)	0.00	0.00	(347.42)	(384.74)	(1,404.78)	(167.38)	0.00	0.00		+35.4 pt
	ROE	—	54.58	51.70	(32.23)	(14.73)	(52.39)	(365.06)	(229.04)	(50.61)	(110.70)	(97.69)		(165.3) pt
People
People	Employees	—	—	39	47	87	74	48	101	104	58	—		+5.8%
	Revenue/emp, $m	—	—	0.00	0.62	0.43	0.19	0.00	0.00	0.02	0.11	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CABA Cabaletta Bio, Inc.	$280.4M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
ABEO Abeona Therapeutics Inc.	$238.5M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
IMRX Immuneering Corporation	$238.3M	— (loss-making)	— (loss-making)	−99.74% (below 0%: shrinking)	n/m	−40.19% (below 0%: shrinking)	0.00%	0.00%	Compare
VNDA Vanda Pharmaceuticals Inc.	$231.0M	— (loss-making)	— (loss-making)	+24.10% (above 0%: growing)	n/m	+9.57% (above 0%: growing)	94.05%	(33.69%)	Compare
ACIU AC Immune	$227.0M	— (loss-making)	— (loss-making)	+152.31% (above 0%: growing)	n/m	+4.66% (above 0%: growing)	100.00%	(302.13%)	Compare
FATE Fate Therapeutics, Inc.	$223.1M	— (loss-making)	— (loss-making)	+9.18% (above 0%: growing)	n/m	+8.96% (above 0%: growing)	100.00%	(1,495.39%)	Compare
GLSI Greenwich LifeSciences, Inc.	$222.7M	— (loss-making)	—	—	n/m	+13.14% (above 0%: growing)	0.00%	0.00%	Compare
KRRO Korro Bio, Inc.	$202.5M	— (loss-making)	— (loss-making)	−86.28% (below 0%: shrinking)	n/m	+12.07% (above 0%: growing)	100.00%	0.00%
SLGL Sol-Gel Technologies Ltd.	$199.8M	— (loss-making)	— (loss-making)	−96.58% (below 0%: shrinking)	n/m	−8.76% (below 0%: shrinking)	100.00%	(704.23%)	Compare
Median of peers	$229.0M	—	—	+16.64%	—	+6.81%	78.68%	(76.83%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 16 April 2026

Ownership

Directors and executive officers, together 4.80%

Lynx1 Master Fund LP 10.70%

Entities affiliated with New Enterprise Associates 9.90%

Entities affiliated with Venrock Healthcare Capital Partners 9.90%

Entities affiliated with Atlas Venture 7.90%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Korro Bio, Inc. (KRRO) Latest News

5 Nov

Impact 3 · 7:00 AM · GlobeNewswire

Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update

23 Oct

Impact 4 · 5:47 AM · Zacks

Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

22 Oct

Impact 4 · 7:00 AM · GlobeNewswire

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

5 Oct

Impact 3 · 4:05 PM · GlobeNewswire

Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121

10 Aug

Impact 3 · 12:00 PM

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

6 Aug

Impact 3 · 7:00 AM

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

19 May

Impact 4 · 7:00 AM · GlobeNewswire

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

7 May

Impact 4 · 7:00 AM · GlobeNewswire

Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update

Impact 4 · 4:30 PM · GlobeNewswire

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

28 Apr

Impact 3 · 12:00 PM · Zacks

What Makes Korro Bio, Inc. (KRRO) a New Buy Stock

16 Apr

Impact 3 · 7:30 AM · GlobeNewswire

Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences

12 Mar

Impact 4 · 4:05 PM · GlobeNewswire

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

9 Mar

Impact 4 · 7:30 AM · GlobeNewswire

Korro Announces Oversubscribed $85 Million Private Placement

13 Feb

Impact 3 · 6:11 AM · Simply Wall St.

We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully

2 Feb

Impact 4 · 9:53 AM · Insider Monkey

H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)

30 Jan

Impact 4 · 3:08 AM · MarketBeat

Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE

Impact 3 · 7:35 AM · Zacks

Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?

20 Jan

Impact 3 · 8:00 AM · GlobeNewswire

Korro to Host Virtual Analyst Day on January 27, 2026

14 Nov

Impact 4 · 10:14 PM · Simply Wall St.

Korro Bio (KRRO): Assessing Valuation After Clinical Setbacks, Layoffs, and Strategic Pivot

13 Nov

Impact 4 · 9:36 AM

Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing

Impact 4 · 6:12 AM · biopharmadive.com

Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing

Impact 3 · 2:18 PM · MT Newswires

Top Midday Decliners

12 Nov

Impact 4 · 4:05 PM · GlobeNewswireMotley FoolGuruFocus.comGuruFocus.comGuruFocus.comMotley FoolMotley Fool

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

Impact 3 · 5:40 PM · Zacks

Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates

2 Sep

Impact 3 · 4:30 PM

Korro to Participate in Upcoming Investor and Scientific Conferences

26 Aug

Impact 4 · 6:58 AM · Simply Wall St.

Is Korro Bio (NASDAQ:KRRO) In A Good Position To Deliver On Growth Plans?

12 Aug

Impact 4 · 7:00 AM

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

21 Jul

Impact 4 · 8:00 AM · GlobeNewswire

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

14 May

Impact 3 · 4:05 PM · GlobeNewswire

Korro to Participate in Upcoming Investor Conferences

9 May

Impact 4 · 10:31 AM · TipRanks

Korro Bio price target lowered to $53 from $130 at H.C. Wainwright

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Korro Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 16 April 2026

Ownership

Korro Bio, Inc. (KRRO) Latest News

5 Nov

23 Oct

22 Oct

5 Oct

10 Aug

6 Aug

19 May

7 May

28 Apr

16 Apr

12 Mar

9 Mar

13 Feb

2 Feb

30 Jan

20 Jan

14 Nov

13 Nov

12 Nov

2 Sep

26 Aug

12 Aug

21 Jul

14 May

9 May

Stockrow Weekly